Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease
with a high risk of recurrent stroke. A recent trial indicated that clopidogrel and aspirin
treatment reduced the risk of recurrent stroke and was not associated with increased
hemorrhage events, compared with aspirin monotherapy. Apixaban, a new oral anticoagulant, is
proved to be as effective as traditional anticoagulants with less risk of bleeding events.
To estimate whether apixaban is beneficial for acute TIA or minor stroke, a randomized,
double-blind, multicenter, controlled clinical trial has been designed. The investigators
will assess the hypothesis that a 21-days apixaban regimen is superior to clopidogrel and
aspirin dual-therapy for the treatment of high-risk patients with acute nondisabling
cerebrovascular event.